Lipid encapsulated interfering RNA

Details Lipid encapsulated interfering RNA Lipid encapsulated interfering RNA

2011-07-19

2011-07-19

Whiteman, Brian (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S458000

Reexamination Certificate

active

07982027

ABSTRACT:
The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell.

REFERENCES:
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4438052 (1984-03-01), Weder et al.
patent: 4515736 (1985-05-01), Deamer
patent: 4598051 (1986-07-01), Papahadjopoulos et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5171678 (1992-12-01), Behr et al.
patent: 5208036 (1993-05-01), Eppstein et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5279833 (1994-01-01), Rose
patent: 5283185 (1994-02-01), Epand et al.
patent: 5320906 (1994-06-01), Eley et al.
patent: 5545412 (1996-08-01), Eppstein et al.
patent: 5578475 (1996-11-01), Jessee
patent: 5641662 (1997-06-01), Debs et al.
patent: 5656743 (1997-08-01), Busch et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5705385 (1998-01-01), Bally et al.
patent: 5820873 (1998-10-01), Choi et al.
patent: 5885613 (1999-03-01), Holland et al.
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 5981501 (1999-11-01), Wheeler et al.
patent: 6165501 (2000-12-01), Tirosh et al.
patent: 6284267 (2001-09-01), Aneja
patent: 6287591 (2001-09-01), Semple et al.
patent: 6534484 (2003-03-01), Wheeler et al.
patent: 6586410 (2003-07-01), Wheeler et al.
patent: 6649780 (2003-11-01), Eibl et al.
patent: 6696424 (2004-02-01), Wheeler
patent: 6815432 (2004-11-01), Wheeler et al.
patent: 6858224 (2005-02-01), Wheeler et al.
patent: 7422902 (2008-09-01), Wheeler et al.
patent: 7803397 (2010-09-01), Heyes et al.
patent: 2001/0048940 (2001-12-01), Tousignant et al.
patent: 2003/0077829 (2003-04-01), MacLachlan
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0063654 (2004-04-01), Davis et al.
patent: 2004/0142892 (2004-07-01), Finn et al.
patent: 2004/0253723 (2004-12-01), Tachas et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0064595 (2005-03-01), MacLachlan et al.
patent: 2005/0118253 (2005-06-01), MacLachlan et al.
patent: 2309727 (1999-04-01), None
patent: 2271582 (1999-11-01), None
patent: 2330741 (1999-11-01), None
patent: 2397016 (2001-07-01), None
patent: 03-126211 (1991-05-01), None
patent: 05-202085 (1993-08-01), None
patent: 06080560 (1994-03-01), None
patent: WO 91/16024 (1991-10-01), None
patent: WO 93/05162 (1993-03-01), None
patent: WO 93/12240 (1993-06-01), None
patent: WO 93/12756 (1993-07-01), None
patent: WO 93/24640 (1993-12-01), None
patent: WO 93/25673 (1993-12-01), None
patent: WO 95/02698 (1995-01-01), None
patent: WO 95/18863 (1995-07-01), None
patent: WO 95/35301 (1995-12-01), None
patent: WO 96/02655 (1996-02-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/41873 (1996-12-01), None
patent: WO 98/51285 (1998-11-01), None
patent: WO 00/03683 (2000-01-01), None
patent: WO 00/15820 (2000-03-01), None
patent: WO 00/62813 (2000-10-01), None
patent: WO/01/05374 (2001-01-01), None
patent: WO 01/05873 (2001-01-01), None
patent: WO/02/34236 (2002-02-01), None
patent: WO 02/087541 (2002-11-01), None
patent: WO 03/097805 (2003-11-01), None
patent: WO 2004/065546 (2004-08-01), None
patent: WO 2004/110499 (2004-12-01), None
patent: WO 2005/007196 (2005-01-01), None
patent: WO 2005/026372 (2005-03-01), None
patent: WO 2005/120152 (2005-12-01), None
Brummelkamp et al. (2002) Science 296:550-553.
Wheeler et al. (1999) Gene Therapy 6:271-281.
Liu et al. (1995) “Cationic liposome-mediated intravenous gene delivery” J. Biol. Chem. 270:24864-24870.
Sorensen et al. (2003) “Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice” J Mol Biol. Apr. 4;327(4):761-6.
Templeton (2002) “Cationic Liposome-mediated Gene Delivery In vivo” Bioscience Reports, vol. 22, No. 2, pp. 283-295.
Bass (2001) Nature 411:428-9.
Lawrence et al. “The formation, characterization and stability of non-ionic surfactant vesicles,” S.T.P. Pharma Sciences, 1996, vol. 6, No. 1, pp. 49-60.
Shin, et al. “Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids,” Journal of Controlled Release, 2003, vol. 91, pp. 187-200.
Chonn et al., “Recent advances in liposomal drug-delivery systems,” Current Opinion in Biotechnology, 1995, pp. 698-708, vol. 6.
Heyes et al., “Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids,” Journal of Controlled Release, 2005, vol. 107, pp. 276-287.
Heyes et al., “Synthesis of novel cationic lipids: effect of structural modification on the efficiency of gene transfer,” J. Med. Chem., 2002, vol. 45, pp. 99-114 .
Lawrence et al., “Synthesis and aggregation properties of dialkyl polyoxyethylene glycerol ethers,” Chemistry and Physics of Lipids, 1996, 82(2):89-100.
Murahashi et al., “Synthesis and evaluation of neoglycolipid for liposome modification,” Biol. Pharm. Bull., 1997, 20(6):704-707.
Parr et al., Factors influencing the retention and chemical stability of polly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles, Biochimica et Biophysica Acta, 1994, 1195:21-30.
Sawada et al., “Microemulsions in supercritical CO2utilizing the polyethyleneglycol dialkylglycerol and their use for the solubilization of hydrophiles,” Dyes and Pigments, 2005, pp. 64-74, vol. 65.
Song et al., “Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes,” Biochimica et Biophysica Acta, 2002, 1558:1-13.
JP06080560—English abstract from CAplus.
Arpicco, S., “Preparation and Characterization of Novel Cationic Lipids Developed for Gene Transfection,” Proceed. Int'l Symp. Control. Rel. Bioact. Mater. (Controlled Release Society, Inc.), 1999, vol. 26, pp. 759-760.
Arpicco, S., et al., “Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids,” IL Farmaco, 2004, vol. 59, pp. 869-878.
Ballas, N., et al., “Liposomes bearing a quaternary ammonium detergent as an efficient vehicle for functional transfer of TMV-RNA into plant protoplasts,” Biochimica et Biophysica Acta, 1988, vol. 939, pp. 8-18.
Barinaga, M., “Step Taken Toward Improved Vectors for Gene Transfer,” Science, 1994, vol. 266, p. 1326.
Beale, G., et al., “Gene Silencing Nucleic Acids Designed by Scanning Arrays: Anti-EGFR Activity of siRNA, Ribozyme and DNA Enzymes Targeting a Single Hybridization-accessible Region using the Same Delivery System,” Journal of Drug Targeting, 2003, vol. 11, No. 7, pp. 449-456.
Behr, J.-P., “Synthetic Gene-Transfer Vectors,” Acc. Chem. Res., 1993, vol. 26, pp. 274-278.
Brigham, K., et al., “Rapid Communication: In vivo Transfection of Murine Lungs with Functioning Prokaryotic Gene Using a Liposome Vehicle,” The American Journal of the Medical Sciences, vol. 298, No. 4, pp. 278-281, 1989.
Cevc, G., “How Membrane Chain-Melting Phase-Transition Temperature is Affected by the Lipid Chain Asymmetry and Degree of Unsaturation: An Effective Chain-Length Model,” Biochemistry, 1991, vol. 30, pp. 7186-7193.
Cortesi, R., et al., “Effect of cationic liposome composition on in vitro cytotoxicity and protective effect on carried DNA,” International Journal of Pharmaceutics, 1996, vol. 139, pp. 69-78.
Crystal, R., “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,” Science, 1995, vol. 270, pp. 404-410.
Culver K., “The First Human Gene Therapy Experiment,” Gene Therapy: A Handbook for Physicians, 1994, pp. 33-40.
Duzgunes, N., “Membrane Fusion,” Subcellular Biochemistry, 1985, vol. 11, pp. 195-286.
Dwarki, V.J., et al., “Cationic Liposome-Mediated RNA Transfection,” Methods in Enzymology, 1993, vol. 217, pp. 644-654.
Enoch, H., et al., &

Affiliated with

Also associated with

Rating

Lipid encapsulated interfering RNA does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipid encapsulated interfering RNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid encapsulated interfering RNA will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2646789